F1ANNEX IIDETERMINATION OF BSE STATUS
CHAPTER DMinimal surveillance requirements
3.Points values and point targets
Surveillance samples must meet the point targets set out in Table 2, on the basis of ‘point values’ fixed in Table 1. All clinical suspects shall be investigated, regardless of the number of points accumulated. A country shall sample at least three out of the four sub-populations. The total points for samples collected shall be accumulated over a period of a maximum of seven consecutive years to achieve the target number of points. The total points accumulation shall be periodically compared to the target number of points for a country or region.
Surveillance sub-population | |||
|---|---|---|---|
Routine slaughter26 | Fallen stock27 | Casualty slaughter28 | Clinical suspect29 |
Age ≥ 1 year and < 2 years | |||
0,01 | 0,2 | 0,4 | N/A |
Age ≥ 2 years and < 4 years (young adult) | |||
0,1 | 0,2 | 0,4 | 260 |
Age ≥ 4 years and < 7 years (middle adult) | |||
0,2 | 0,9 | 1,6 | 750 |
Age ≥ 7 years and < 9 years (older adult) | |||
0,1 | 0,4 | 0,7 | 220 |
Age ≥ 9 years (aged) | |||
0,0 | 0,1 | 0,2 | 45 |
Bovine animals over 36 months of age at routine slaughter. | |||
Bovine animals over 30 months of age which are found dead or killed on farm, during transport or at an abattoir (fallen stock). | |||
Bovine animals over 30 months of age that are non-ambulatory, recumbent, unable to rise or to walk without assistance; bovine animals over 30 months of age sent for emergency slaughter or with abnormal observations at ante-mortem inspection (casualty or emergency slaughter). | |||
Bovine animals over 30 months of age displaying behavioural or clinical signs consistent with BSE (clinical suspects). | |||
Points targets for country or region | ||
|---|---|---|
Adult bovine animals population size(24 months and older) | Type A surveillance | Type B surveillance |
> 1 000 000 | 300 000 | 150 000 |
900 001-1 000 000 | 214 600 | 107 300 |
800 001-900 000 | 190 700 | 95 350 |
700 001-800 000 | 166 900 | 83 450 |
600 001-700 000 | 143 000 | 71 500 |
500 001-600 000 | 119 200 | 59 600 |
400 001-500 000 | 95 400 | 47 700 |
300 001-400 000 | 71 500 | 35 750 |
200 001-300 000 | 47 700 | 23 850 |
100 001-200 000 | 22 100 | 11 500 |
90 001-100 000 | 19 900 | 9 950 |
80 001-90 000 | 17 700 | 8 850 |
70 001-80 000 | 15 500 | 7 750 |
60 001-70 000 | 13 000 | 6 650 |
50 001-60 000 | 11 000 | 5 500 |
40 001-50 000 | 8 800 | 4 400 |
30 001-40 000 | 6 600 | 3 300 |
20 001-30 000 | 4 400 | 2 200 |
10 001-20 000 | 2 100 | 1 050 |
9 001-10 000 | 1 900 | 950 |
8 001-9 000 | 1 600 | 800 |
7 001-8 000 | 1 400 | 700 |
6 001-7 000 | 1 200 | 600 |
5 001-6 000 | 1 000 | 500 |
4 001-5 000 | 800 | 400 |
3 001-4 000 | 600 | 300 |
2 001-3 000 | 400 | 200 |
1 001-2 000 | 200 | 100 |
Substituted by Commission Regulation (EC) No 722/2007 of 25 June 2007 amending Annexes II, V, VI, VIII, IX and XI to Regulation (EC) No 999/2001 of the European Parliament and of the Council laying down rules for the prevention, control and eradication of certain transmissible spongiform encephalopathies (Text with EEA relevance).